Approved for Active immunization of pregnant individuals at 32 through 36 weeks gestational age for prevention of RSV-associated lower respiratory tract disease in infants from birth through 6 months of age. RSV vaccine (bivalent, recombinant) administered during pregnancy stimulates maternal antibody production against RSV prefusion F protein. These antibodies are transferred to the fetus via…
Loading full data from Know Your Drugs Institute…